Back to trial details

Intake questionnaire

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Applying to University of Illinois Cancer Center · Chicago, Illinois

Answer a few short questions to share with the research team.

0 of 4 answered

1. Are you 18 years old or older?
2. Have you been diagnosed with Hormone Receptor Positive HER-2 Negative Breast Cancer?
3. Are you currently pregnant or breastfeeding?
4. Are you able to travel to Chicago for study visits?